ProQR Therapeutics NV 2026年年度报告和过渡报告

FORM20-F OR ☒ANNUAL REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 OR ☐SHELL COMPANY REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report: Not applicableFor the transition period fromto Commission file number 001-36622 PROQR THERAPEUTICS N.V.(Exact name of Registrant as specified in its charter) The Netherlands(Jurisdiction of incorporation or organization)Zernikedreef 92333 CK LeidenThe Netherlands(Address of principal executive offices)Dennis Hom, Chief Financial OfficerTel: +31 88 166 7000ir@proqr.com, Zernikedreef 9, 2333 CK Leiden, The Netherlands(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Table of Contents Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act.◻Yes⌧No If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reportspursuant to Section13 or 15(d)of the Securities Exchange Act of 1934.◻Yes⌧No Note– Checking the box above will not relieve any registrant required to file reports pursuant to Section13 or 15(d) of theSecurities Exchange Act of 1934 from their obligations under those Sections. Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days.⌧Yes◻No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files).⌧Yes◻No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or anemerging growth company. See definition of “large accelerated filer”, “accelerated filer”, and “emerging growthcompany” in Rule12b-2 of the Exchange Act. (Check one): If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards†provided pursuant to section 13(a) of the Exchange Act.◻ †The term “new or revised financial accounting standard” refers to any update issued by the FinancialAccounting Standards Board to its Accounting Standards Codification after April 5, 2012. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statementsof the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis ofincentive based compensation received by any of the registrant’s executive officers during the relevant recovery periodpursuant to §240.10D-1(b). Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included inthis filing:◻U.S. GAAP⌧International Financial Reporting◻Other Standards as issued by the InternationalAccounting Standards BoardIf “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.◻Item17◻Item18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes⌧No Summary of the Material and Other Risks Associated with Our Business Our business is subject to numerous material risks and uncertainties that you should be aware of in evaluating ourbusiness, including those described in Part I, Item 3.D: “Risk Factors” in this Annual Report on Form 20-F, or this AnnualReport. These risks include, but are not limited to, the following: ●We are a biopharmaceutical company with a history of losses. We expect to continue to incur significant lossesfor the foreseeable future and may never achieve or maintain profitability, which could result in a decline in themarket value of our ordinary shares.●We will require additional capital to fund our operations and if we fail to obtain necessary fin